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Abstract
Objectives: Emerging evidence suggests that fatigue in myasthenia gravis (MG) is a 
relevant problem that negatively impacts activities of daily living (ADL). The relation-
ship between fatigue and quality of life (QoL) has never been systematically explored 
in MG patients. The study aimed to assess the prevalence of fatigue and its relation to 
ADL and QoL as well as to identify factors associated with fatigue in MG.
Material and Methods: This was a cross- sectional observational study in patients with 
confirmed diagnosis of MG independent of disease severity. Prevalence of fatigue was 
assessed using the Chalder Fatigue Scale (CFQ). Impact of fatigue on ADL and QoL 
was assessed by the MG activities of daily living profile (MG- ADL) and the MG- specific 
quality- of- life instrument (MG- QoL), respectively. Association of fatigue with sociode-
mographics, clinical characteristics of MG, and comorbidities including mood and anxi-
ety disorders as well as sleep disorders was investigated using multivariable logistic 
regression analyses.
Results: Overall, 200 MG patients were included. The observed rate of fatigue was 
56.1%, of those 70.4% fulfilled the criteria of chronic fatigue (CF) with a duration of 
≥6 months. Relevant fatigue was strongly associated to ADL and QoL. Factors associ-
ated with relevant fatigue were disease severity and depressive state. Furthermore, 
positive muscle- specific tyrosine kinase (MuSK) antibody status showed a strong asso-
ciation with relevant fatigue.
Conclusions: MG patients have a high prevalence of fatigue which negatively impacts 
ADL and QoL. MG- specific clinical characteristics are related to fatigue and might help 
to identify MG patients at risk for fatigue.
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1  | INTRODUCTION
Fluctuating, painless muscle weakness is usually referred to as cardi-
nal symptom of myasthenia gravis (MG; Cejvanovic & Vissing, 2014; 
Grob, Brunner, Namba, & Pagala, 2008). However, the clinical picture 
of MG is more complex and emerging evidence recognizes fatigue as 
a relevant problem in MG (Elsais, Wyller, Loge, & Kerty, 2013; Paul, 
Cohen, Goldstein, & Gilchrist, 2000). Previous studies reported fatigue 
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prevalence rates between 75% and 89% in MG patients (Kluger, 
Krupp, & Enoka, 2013) and qualitative data suggest that, in some 
patients, fatigue has a greater impact on daily living of MG patients 
than has muscle weakness (Barnett, Bril, Kapral, Kulkarni, & Davis, 
2014; Zwarts, Bleijenberg, & van Engelen, 2008). However, overall 
literature on fatigue in MG is scarce and its impact on activities of dai-
ly living (ADL) and quality of life (QoL) has never been systematically 
explored. This might be due to various reasons. Fatigue is a complex, 
nonspecific, and highly subjective symptom and therefore difficult 
to evaluate and quantify (Krupp, LaRocca, Muir- Nash, & Steinberg, 
1989; Norheim, Jonsson, & Omdal, 2011). The fluctuating and effort- 
dependent nature of fatigue makes it even more difficult to separate 
fatigue from muscle fatigability in MG. We follow recent proposals 
to use the term fatigue to refer to subjective sensations of exhaus-
tion and muscle fatigability to refer to objective changes in muscle 
performance (Kluger et al., 2013). Other related phenomena such as 
depression and sleep disorders need to be distinguished from fatigue 
and should therefore be included as covariates when assessing fatigue 
(Kluger et al., 2013). Finally, the understanding of the pathophysiolo-
gy of fatigue is limited. MG is an autoimmune- mediated disease with 
autoantibodies directed against components of the postsynaptic mus-
cular endplate (Szczudlik et al., 2014). The most likely confinement to 
the peripheral nervous system makes hypotheses on the pathophysi-
ology of fatigue in MG particularly challenging.
The aim of the present study was to assess the prevalence of 
fatigue and its impact on ADL and QoL in a large cohort of MG patients 
as well as to identify factors associated with fatigue including MG- 
specific clinical characteristics as well as potential confounders such as 
mood and sleep disturbances (Elsais et al., 2013; Kluger et al., 2013).
2  | MATERIAL AND METHODS
2.1 | Patients
This was a cross- sectional, observational study performed at the certi-
fied Integrated Center for Myasthenia gravis (IMZ) of the Charité – 
Universitätsmedizin Berlin, Germany. Patients over the age of 18 years 
with confirmed diagnosis of myasthenia gravis were included inde-
pendent of disease duration and severity (excluding myasthenic cri-
sis). Patients were consecutively screened at the IMZ clinic between 
December 2012 and December 2013.
Sociodemographics (age, sex), current MG- specific medication 
(cholinesterase inhibitors, glucocorticoids, and long- term immunosup-
pressants), current comedication (antidepressants, NSAIDs, and opi-
oids), and comorbidities (other immunopathies, cardiac insufficiency, 
and malignancies) were collected in a database. Clinical assessment 
was performed using the MGFA classification for disease classification 
(Jaretzki et al., 2000) and the QMG score for disease severity. Using 
the MGFA classification, patients were grouped into ocular (MGFA I) 
or generalized MG patients (MGFA II–IV) at the time of study inclu-
sion. According to current recommendations, we used the MGFA clas-
sification by employing the most severely affected muscles to define 
the patient’s MGFA class (the “maximum severity” designation being 
made historically; Jaretzki et al., 2000). Thereby, patients were only 
assigned to MGFA I if symptomatology was restricted to purely ocular 
symptoms throughout the patient’s entire disease history (ocular MG). 
Correspondingly, patients with generalized symptoms (affecting limb/
axial and/or bulbar/respiratory muscles) throughout their disease his-
tory were assigned to generalized MG. An exception to this approach 
was made in patients without any detectable myasthenic weakness 
under current medication who were assigned to “pharmacological 
remission.”
2.2 | Questionnaires
All patients completed the self- assessment questionnaires at the 
IMZ. Completion of questionnaires required approximately 30 min. 
If available, validated German versions of questionnaires were used, 
as in the case of the Chalder Fatigue Scale (CFQ; Martin, Gaab, Rief, 
& Brähler, 2010) and the Hospital Anxiety and Depression Scale 
(HADS; Hinz & Schwarz, 2001). The other questionnaires (Insomnia 
Severity Index, MG activities of daily living profile, and MG- specific 
quality- of- life instrument) were translated using forward–backward 
translation procedure by two physicians (SH, JR) who are both 
native German with excellent knowledge of English. The transla-
tions were reviewed by the principal investigator (AM). In case of 
discrepancies, a reconciled version was produced by a consensus 
conference.
2.2.1 | Chalder Fatigue Scale
For assessing fatigue, the CFQ presented by Chalder et al. (1993) 
was used. The CFQ is a self- administered questionnaire for meas-
uring the severity of physical (CFQ- P) and mental (CFQ- M) fatigue 
within both clinical and epidemiological populations (Jackson, 2015). 
It consists of 11 items that are answered on a 4- point scale rang-
ing from the asymptomatic to maximum symptomatology, such as 
“less than usual,” “no more than usual,” “more than usual,” and “much 
more than usual” offering the option of binary scoring (0 0 1 1) or 
Likert scoring (0 1 2 3). We used the binary scoring (total score 0–11) 
to define caseness in patients with a score of 4 points or higher as 
proposed by Chalder et al. and the Likert scoring (total score 0–33) 
to evaluate mean fatigue scores in the different fatigue domains. To 
differentiate between transient and chronic fatigue (CF), we assessed 
fatigue duration by asking if symptoms were present for <6 months 
or longer.
2.2.2 | MG- specific quality- of- life instrument
MG- specific quality- of- life instrument (MG- QoL) is a 15- item ques-
tionnaire encompassing physical and psychological domains of MG to 
assess disease- specific QoL in MG patients (Burns, Conaway, Cutter, 
& Sanders, 2008). Rating consists of a 5- point scale ranging from 0 
(“not at all”) to 4 (“very much”) as to the degree to which patients 
agree with the given statement summing up to a total score of 0–60 
points.
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2.2.3 | MG activities of daily living profile
Impact on daily living was assessed using the MG activities of daily liv-
ing profile (MG- ADL; Wolfe et al., 1999). It is an eight- question survey 
of symptom severity, with each response graded from 0 (normal) to 
3 (most severe). Questions include ocular, oropharyngeal, respiratory, 
and extremity functions. Total MG- ADL score ranges from 0 to 24.
2.2.4 | Hospital anxiety and depression scale
Hospital anxiety and depression scale is a self- assessment mood 
scale developed to identify cases of anxiety disorders and depression 
among patients in nonpsychiatric hospital clinics (Zigmond & Snaith, 
1983). It is divided into an anxiety subscale (HADS- A) and a depres-
sion subscale (HADS- D) both containing seven items (Bjelland, Dahl, 
Haug, & Neckelmann, 2002) with a 0- to 3- point Likert response for-
mat summing up to a total score of 21 for each subscale. A cut- off 
score of 8 or higher on each subscale was used to define caseness of 
anxiety and depression, respectively (Bjelland et al., 2002). Symptoms 
of mood disorders likely to be present in somatic disorders (e.g., 
insomnia, fatigue, anorexia) are excluded in the HADS.
2.2.5 | Insomnia Severity Index
Sleep disturbances were assessed using the ISI. It is a seven- item self- 
report instrument targeting the subjective symptoms and consequenc-
es of insomnia (Bastien, Vallieres, & Morin, 2001). Using the Likert scale, 
each item is rated between 0 to 4 points summing up to a total score 
range from 0 to 28. We used a cut- off score of 10 points to define case-
ness of sleep disturbances (Morin, Belleville, Belanger, & Ivers, 2011).
2.3 | Statistical analysis
Descriptive analyses included reports of means and standard devia-
tion, median and interquartile range (IQR), or absolute and relative 
frequencies depending on the scale and distribution of variables. We 
compared sociodemographic characteristics, questionnaire scores, 
and clinical characteristics between the myasthenia subgroups using 
Fisher’s exact test, chi- square test, one- way ANOVA, or Kruskal–
Wallis test where indicated (Tables 1 and 2). To analyze association of 
characteristics with clinical- relevant fatigue, we used t- test, Mann–
Whitney test, Fisher’s exact test, or chi- square test (Table 3). In mul-
tiple logistic regression analysis we included and tested variables that 
were associated with relevant fatigue in univariate analysis (p < .05). 
As all six MuSK- ab- positive patients had relevant fatigue, the prob-
lem of quasi- separation appears resulting in nonexistence of OR and 
CI estimates. Therefore, Firth logistic regression was used (Stata/IC 
13.1 command firthlogit), estimating ORs and CIs with penalized likeli-
hood estimation methods (Heinze & Schemper, 2002). Only significant 
variables remained in the final model with the exception of MuSK- ab 
which was forced into the model. We used a two- sided significance 
level of alpha = 0.05. Linear regression was used to analyze associa-
tion of relevant fatigue with ADL and QoL adjusted for MG type (one 
regression model for each outcome, Fig. 1). No adjustment for multi-
ple testing was applied as this is an exploratory study. Statistical tests 
were performed using SPSS 22 (IBM, Armonk, NY, USA).
TABLE  1 Baseline characteristics
Characteristic All GMG OMG Remission p- value
n (%) 200 119 39 42
Age, year, mean (SD) 58 (17) 56 (17) 60 (15) 61 (17) .235
Age at disease onset, mean (SD) 48 (20) 45 (21) 53 (17) 52 (20) .032
Female sex, n (%) 107 (53.5) 76 (63.9) 12 (30.8) 19 (45.2) .001
Disease duration, year, median (IQR) 6 (2–15) 7 (3–16) 3 (2–10) 6 (2–10) .014
Antibody status, n (%) (1 missing)
AchR 166 (83.4) 98 (83.1) 30 (76.9) 38 (90.5) .258
MuSK 6 (3.0) 5 (4.2) 1 (2.6) — .535
Negative 27 (13.6) 15 (12.7) 8 (20.5) 4 (9.5) .322
Medication, n (%)
Cholinesterase inhibitors 173 (86.5) 107 (89.9) 37 (94.9) 29 (69.0) .001
Glucocorticoids 111 (55.5) 68 (57.1) 23 (59.0) 20 (47.6) .502
Immunosuppressants 116 (58.0) 81 (68.1) 10 (25.6) 25 (59.5) <.001
None 4 (2.0) 1 (0.8) – 3 (7.1) .064
Thymectomy, n (%) (9 missings) 99 (51.8) 68 (59.6) 9 (24.3) 22 (55.0) .001
Thymoma 24 (24.2) 18 (75.0) 3 (12.5) 3 (12.5) .380
Thymus hyperplasia 31 (31.3) 21 (67.7) 2 (6.5) 8 (25.8) .736
Comedication, n (%)
Antidepressants 18 (9.0) 15 (12.6) 2 (5.1) 1 (2.4) .089
NSAIDs 13 (6.5) 8 (6.7) 2 (5.1) 3 (7.1) .924
Opioids 8 (4.0) 7 (5.9) 1 (2.6) 0 (0.0) .217
GMG, generalized myasthenia gravis; OMG, ocular myasthenia gravis; AchR, acetylcholine receptor; MuSK, muscle- specific tyrosine kinase.
p- values refer to overall group comparisons of patients with generalized MG, ocular MG, and pharmacological remission.
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2.4 | Ethics
The study was approved by the ethics committee of the Charité – 
Universitätsmedizin Berlin (EA1/281/10). All patients gave written 
informed consent in accordance with the Declaration of Helsinki in its 
currently applicable form.
3  | RESULTS
3.1 | Patient’s demographic and clinical 
characteristics
Overall, 200 patients were included. Mean age was 58 years (SD: 17), 
107 (53.5%) were female. Most patients were positive for AchR- ab 
(n = 166, 83.4%), 6 (3.0%) patients were positive for MuSK- ab, and 27 
(13.6%) patients were double seronegative. About half of the patients 
(n = 99, 49.5%) had undergone thymectomy. Of those who had under-
gone thymectomy, 24 (24.2%) had thymoma and 31 (31.3%) patients 
revealed thymus hyperplasia in the histological examination. Among 
the patients taking long- term immunosuppressant drugs (n = 116, 
58%), 85 (42.5%) patients took azathioprine, 16 (8%) patients took 
methotrexate, 14 (7%) patients took mycophenolate mofetil, and 
1 (0.5%) patient took cyclosporine A. Median disease duration was 
6 years (IQR: 2–15). Table 1 shows the baseline characteristics for MG 
patients in total and stratified by GMG, OMG, and pharmacological 
remission.
3.2 | Fatigue prevalence and severity
Relevant fatigue (CFQ ≥ 4 points on the binary scale) was present in 
110 (56.1%) of MG patients (Table 2). Rates of relevant fatigue ranged 
from 31.7% in patients in pharmacological remission to 71.6% in 
patients with generalized MG (p < .001). GMG patients had signifi-
cantly higher CFQ scores (Likert scale) in the physical as well as in the 
mental domain compared to remitted MG as well as OMG patients 
(Table 2). Within the group of patients with relevant fatigue, chronic 
fatigue (≥6 months) was similarly distributed among patients with 
GMG (72.0%) compared to patients with OMG (64.3%) or patients in 
pharmacological remission (66.7%).
3.3 | Prevalence of mood, anxiety, and 
sleep disorders
Using a cut- off score of ≥8 points on the HADS, rates for depres-
sion and anxiety in the total sample are 19.6% and 27.8%, respectively 
(Table 2). Rate of sleeping disturbances defined as a cut- off score of 
≥10 points on the ISI were 41.5%. Both, mood and sleeping disorders 
were more frequent in patients with GMG compared to those with 
OMG or in pharmacological remission.
3.4 | Factors associated with relevant fatigue: 
univariate and multivariate analysis
The following characteristics were associated with relevant fatigue 
in univariate analysis (Table 3): female sex, GMG, positive AchR or 
MuSK antibody status, medication with cholinesterase inhibitors or 
opioids, thymectomy, presence of other immunopathies, higher QMG 
score, higher HADS- D and HADS- A scores, and higher ISI score. 
Multivariable logistic regression showed that higher QMG score and 
higher HADS- D score were significantly associated with relevant 
fatigue after adjustment for each other and for positive MuSK- ab sta-
tus (Table 4). Positive MuSK- ab status showed a strong association 
with relevant fatigue, although due to the low case number this find-
ing did not reach statistical significance.
3.5 | Fatigue and its association with quality of 
life and activities of daily living
Figure 1 shows that quality of life as measured by the MG- QoL15 
and activities of daily living as measured by the MG- ADL scores were 
TABLE  2 Prevalence and severity of relevant fatigue, prevalence of mood, anxiety, and sleep disorders
Parameter All GMG OMG Remission p- value
n 196 116 39 41
CFQ ≥ 4 items, n (%) 110 (56.1) 83 (71.6) 14 (35.9) 13 (31.7) <.001
CFQ- T score, mean (SD) 15.6 (6.2) 17.5 (6.0) 14.0 (5.6) 11.7 (5.0) <.001
CFQ- P score, mean (SD) 10.7 (4.5) 12.1 (4.3) 9.4 (4.1) 7.8 (3.7) <.001
CFQ- M score, mean (SD) 4.9 (2.3) 5.4 (2.4) 4.7 (2.2) 3.9 (1.9) .002
CF ≥ 6 months within n = 108 patients with 
relevant fatigue, n (%) (2 missings)
76 (70.4) 59 (72.0) 9 (64.3) 8 (66.7) .808
HADS- D ≥ 8 points, n (%) (6 missings) 38 (19.6) 28 (24.6) 6 (15.4) 4 (9.8) .093
HADS- A ≥ 8 points, n (%) (6 missings) 54 (27.8) 41 (36.0) 7 (17.9) 6 (14.6) .010
ISI ≥ 10 points, n (%) 83 (41.5) 61 (51.3) 12 (30.8) 10 (23,8) .003
GMG, generalized myasthenia gravis; OMG, ocular myasthenia gravis; CFQ, Chalder Fatigue Scale; CFQ- T, CFQ- Total; CFQ- P, CFQ- Physical; CFQ- M, 
CFQ- Mental; CF, chronic fatigue (≥6 months); ISI, Insomnia Severity Index; HADS, Hospital Anxiety and Depression Scale; HADS- D, HADS- Depression; 
HADS- A, HADS- Anxiety; MG- ADL, MG activities of daily living profile.
p- values refer to overall group comparisons of patients with generalized MG, ocular MG, and pharmacological remission.
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significantly higher (higher scores indicating more severe symptoms) in 
patients with relevant fatigue (p < .001). Within the group of patients 
with relevant fatigue, mean MG- QoL score was 22.7 points in GMG 
patients compared to patients with OMG (19.3) and patients in phar-
macological remission (8.6). Mean MG- ADL score within the group of 
patients with relevant fatigue was 6.2 points in GMG patients com-
pared to patients with OMG (4.8 points) and patients in pharmacologi-
cal remission (3.3 points).
4  | DISCUSSION
Our study adds to the scarce literature on fatigue in MG by demon-
strating a high prevalence of fatigue among MG patients and showing 
a negative impact of fatigue on QoL in MG patients. Furthermore, we 
identified disease severity and depressive state as independent risk 
factors associated with fatigue in MG patients.
The prevalence of fatigue in our MG cohort was 56.1%. A recent 
study by Elsais et al. (2013) using the same questionnaire in a 
Norwegian MG population reported a fatigue rate of 44%. The high-
er fatigue rate in our cohort might be explained by a higher disease 
severity. Elsais et al. (2013) only included patients with MGFA grade 
II or better, whereas we only excluded patients with myasthenic crisis. 
Consistently, a higher QMG score was associated with a higher prev-
alence of relevant fatigue. It is noteworthy, that the QMG score is an 
instrument to measure muscle fatigability, not fatigue. The authors 
are aware of the challenge of separating fatigue from muscle fatiga-
bility. Fatigue is a multidimensional concept covering both physical 
and psychological aspects making it difficult to assess fatigue in neu-
rological diseases in general and in MG in particular. However, the 
high prevalence of fatigue in our cohort and its negative impact on 
ADL and QoL underline the need of further research on fatigue in MG. 
Moreover, one third of MG patients in pharmacological remission in 
our cohort suffered from relevant fatigue. Our finding is consistent 
with the results of Elsais et al. (2013) suggesting that factors other 
than myasthenic muscle weakness are involved in the pathogenesis 
of fatigue in MG. Furthermore, the distinction between fatigue and 
muscle fatigability might be of practical relevance, for example, might 









n (%) 110 (56.1) 86 (43.9)
Age, year, mean (SD) 59 (17) 58 (16) .951
Age at disease onset, mean (SD) 48 (20) 48 (21) .975
Female sex, n (%) 68 (66.0) 35 (34.0) .003
Disease duration, year, median 
(IQR)
7 (3–14) 5 (2–15) .881
QMG score, mean (SD) 9.9 (6.0) 4.4 (4.0) <.001
ISI score, mean (SD) 11.6 (7.2) 5.5 (5.1) <.001
ISI ≥ 10 points, n (%) 63 (79.7) 16 (20.3)
HADS- D, mean (SD) 6.5 (3.6) 2.2 (2.4) <.001
HADS- D ≥ 8 points, n (%) 34 (89.5) 4 (10.5)
HADS- A, mean (SD) 6.9 (3.8) 3.8 (3.2) <.001
HADS- A ≥ 8 points, n (%) 42 (77.8) 12 (22.2)
Antibody status, n (%)
AchR 85 (52.5) 77 (47.5) .033
MuSK 6 (100) 0 (0.0) .035
Negative 18 (66.7) 9 (33.3) .225
Medication, n (%)
Cholinesterase inhibitors 100 (59.2) 69 (40.8) .031
Glucocorticoids 67 (60.4) 44 (39.6) .172
Immunosuppressants 69 (61.1) 44 (38.9) .104
None 1 (25.0) 3 (75.0) .321
Thymectomy, n (%) (9 missings) 60 (63.2) 35 (36.8) .050
Thymoma 11 (47.8) 12 (52.2) .080
Thymus hyperplasia 18 (62.1) 11 (37.9) .884
Comorbidities
Other immunopathies 34 (68.0) 16 (32.0) .050
Malignancies 3 (42.9) 4 (57.1) .701
NYHA 5 (83.3) 1 (16.7) .233
Comedication, n (%)
Antidepressants 13 (72.2) 5 (27.8) .149
NSAIDs 9 (75.0) 3 (25.0) .174
Opioids 8 (100.0) 0 (0.0) .011
QMG, quantitative myasthenia gravis score; ISI, Insomnia Severity Index; 
HADS, Hospital Anxiety and Depression Scale; HADS- D, HADS- 
Depression; HADS- A, HADS- Anxiety; AchR, acetylcholine receptor; 
MuSK, muscle- specific tyrosine kinase; CFQ, Chalder Fatigue Scale.
F IGURE  1 Subgroup analyses of 
MGQoL15 and MGADL stratified by relevant 
fatigue and disease classification. MGQoL15 
and MGADL scores are significantly higher 
in patients with relevant fatigue. Within 
the group of patients with relevant fatigue, 
patients with GMG have significantly higher 
MG- QoL and MGADL scores compared to 
patients with in pharmacological remission. 
*p ≤ .05, **p ≤ .01, ***p ≤ .001. GMG, 
generalized myasthenia gravis; OMG, ocular 
myasthenia gravis; CFQ, Chalder Fatigue 
Scale; MGQoL15, MG- specific quality- of- life 
instrument; MGADL, MG activities of daily 
living profile
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require different therapeutical approaches. To the best of our knowl-
edge, there is no interventional study on fatigue in MG. One study 
reported an improvement of fatigue after supplementation of vita-
min D3 (Askmark, Haggard, Nygren, & Punga, 2012). However, in this 
study fatigue was assessed using the MG composite scale, thereby 
mainly measuring muscle fatigability rather than fatigue. Awareness 
for the need of separating fatigue from muscle fatigability in MG is 
only beginning to rise. More studies on this topic are warranted to 
reproduce our findings or to unravel other factors associated with 
fatigue. If, for example, disease severity showed a consistent associ-
ation with fatigue in MG, an escalation of symptomatic and/or immu-
nosuppressive therapy could be an approach to treat fatigue in MG. 
Treatment of fatigue itself should consist of a stepwise approach of 
psychological, physical, and pharmacological interventions. The lat-
ter is particularly challenging in MG because MG symptoms can be 
worsened by a variety of drugs.
We included measures of mood and sleep disturbances as covari-
ates in our analyses as recommended by other research groups 
(Elsais et al., 2013; Kluger et al., 2013). Depressive state was asso-
ciated with higher prevalence of fatigue. The association between 
fatigue and depression is widely accepted and mainly attributed to 
the overlap in symptomatology between fatigue and depression 
(such as physical fatigue; Norheim et al., 2011). Rate of depressive 
state was 19.6% in our MG cohort and thereby comparable to those 
in the general German population (Hinz & Brahler, 2011). It has long 
been suggested that depression is common among MG patients 
(Chafetz, 1966; Meyer, 1966). However, more recent studies show 
inconsistent results. Although some studies report markedly higher 
depression rates of up to 33% in MG patients (Fisher, Parkinson, & 
Kothari, 2003; Magni et al., 1988), others have found no increased 
frequency of depression in MG patients over the general population 
(Doering, Henze, & Schussler, 1993; Tennant, Wilby, & Nicholson, 
1986). These conflicting results might be partially attributable to 
the use of different measures of depression across the studies. 
The use of the HADS which was developed to identify caseness of 
anxiety disorders and depression among patients in nonpsychiatric 
hospital clinics and therefore excludes physical symptoms might be 
particularly suitable to overcome the overlap in symptomatology 
between MG, fatigue, depression, and sleep disorders.
Positive MuSK antibody status shows a strong influence on rel-
evant fatigue, although this finding did not reach statistical signifi-
cance. This might be due to the low case number (n = 6). However, 
the prevalence of MuSK- positive patients among AchR- negative 
patients was 17.6% and thereby comparable to the prevalence of 
other European MG cohorts (Kostera- Pruszczyk et al., 2008; Niks, 
Kuks, & Verschuuren, 2007). Attempts have been made to better 
characterize MG patients by their antibody status and differences 
were found for patterns of involved muscles, disease severity, as 
well as treatment responses (Ohta et al., 2007). Interestingly, all of 
the MuSK- positive MG patients reported relevant fatigue. Due to 
the low case number, this finding needs to be interpreted with cau-
tion but MuSK- ab and their association with relevant fatigue seem 
to be a promising target for further investigations. Future studies on 
fatigue in MG should furthermore consider newly described anti-
bodies such as anti- LRP4 and anti- Agrin antibodies (Gasperi et al., 
2014).
Our study has several limitations that need to be acknowledged. 
The study design did not include a healthy control group to compare 
our data with. However, the herein used CFS allows for compari-
sons of fatigue prevalence in the general population (Martin et al., 
2010) and other MG cohorts (Elsais et al., 2013). Main objectives 
of our study were furthermore the identification of clinical factors 
associated with fatigue in MG assessing QoL and ADL with MG- 
specific self- questionnaires which could not have been performed 
in a group of healthy controls. Patients were grouped into OMG and 
GMG patients by employing the most severely affected muscles to 
define the patient’s MGFA class. This might have introduced a bias 
as GMG patients could have presented with purely ocular symp-
toms at study inclusion. However, in our experience, a mild affec-
tion of other than purely ocular muscles is noticeable for most GMG 
patients. For some of the questionnaires used in this study (ISI, MG- 
ADL, MG- QoL), validated German versions were not available which 
might have influenced the results. Statistical analysis did not include 
multiple testing. However, this was an exploratory analysis without 
any predefined hypotheses and predictors for relevant fatigue were 
identified using multivariable regression analysis. Further limita-
tions include potential shortcomings concerning the clinical factors 
included in our analyses. For example, comedication did not consider 
hypnotics and betablockers despite their reported negative effect 
on fatigue (Braley, Segal, & Chervin, 2015; Tang, Yu, & Yeh, 2010). 
The test battery with five self- assessment questionnaires might have 
influenced the results. Patients were free to decide on the order of 
questionnaire completion, therefore, we cannot entirely exclude 
an overestimation of mental fatigue due to prior concentration on 
completion of other questionnaires. However, increasing emphasis 
has been placed on self- reporting instruments as they allow for an 
assessment of highly subjective conditions such as fatigue as well 
as for an evaluation of the impact of diseases such as QoL and ADL 
(Wolfe et al., 1999).
In conclusion, our study emphasizes the importance of fatigue 
in MG even in patients in pharmacological remission and its impact 
on ADL and QoL. MG- specific clinical characteristics seem to have 
TABLE  4 Factors associated with clinically relevant fatigue: final 
multivariable analyses
Characteristic
Relevant fatigue (CFQ ≥ 4) 
OR (95% CI)
QMG score 1.17 (1.07–1.27)
HADS- D 1.55 (1.31–1.82)
MuSK 15.63 (0.67–362.46)
QMG, quantitative myasthenia gravis score; HADS- D, Hospital Anxiety 
and Depression Scale- Depression; MuSK, muscle- specific tyrosine kinase; 
CFQ, Chalder Fatigue Scale.
Firth regression model (n = 173), odds ratios (OR), and 95% CI (Tjur’s 
r2 = .45) (MuSK- ab was forced into the model, otherwise only significant 
coefficients remained in the final model).
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an influence on fatigue and might help to identify MG patients at 
risk for fatigue. Fatigue could be misinterpreted as muscle fati-
gability or mood disorders. Therefore, depressive state should be 
assessed excluding physical symptoms of depression in order to 
avoid overestimation of depressive state in MG patients. Future 
clinical trials in MG should include fatigue as endpoint in order to 
assess if fatigue changes with improvement of disease severity or 
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